Vincenzi B1, Stumbo L1, Maltese G2, Cerbone L3, Spalato Ceruso M1, Badalamenti G2, Santini D1, Tonini G1, Frezza AM1, De Lisi D1, Silletta M1.
Author information1Medical Oncology, University campus Bio-Medico, Rome, Italy.2Department of Medical Oncology, Policlinico P. Giaccone, Palermo, Italy.3Medical Oncology, Ospedale San Camillo Forlanini, Rome, Italy.
Elevation in liver transaminases is common in patients treated with the marine antitumor agent trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment outcomes is unclear. This retrospective study investigated the correlation between liver tests abnormalities and treatment outcomes in patients with unresectable advanced or metastatic soft tissue sarcomas (STS) treated with trabectedin 1.5 mg/m2 once every 3 weeks at three reference centers in Italy. The effect of grade 3/4 elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the first two cycles and at any time during trabectedin treatment on progression-free survival (PFS) and overall survival (OS) were analyzed. Liver tests abnormalities during the first two cycles of chemotherapy or at any time during trabectedin treatment did not significantly affect PFS or OS. Nor were survival outcomes significantly different in the subgroups of patients with or without ALT/AST increases or with ALT/AST elevations ≥ 15 × the upper limit of normal (ULN) versus those with ALT/AST elevation < 15 × ULN. Although liver tests abnormalities are common in patients treated with trabectedin , elevations in ALT and AST are usually transient, occur during the first two cycles of treatment, and do not appear to affect survival.